NCT06387420 - A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

April 29, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

ACUTE MYELOID LEUKEMIA; AML

Interventions

DRUG

AK117

Subjects receive AK117 intravenously.

DRUG

Azacitidine

Subjects receive azacitidine subcutaneously.

DRUG

Venetoclax

Subjects receive venetoclax orally.

OTHER

Placebo

Subjects receive placebo intravenously.

Trial Locations (1)

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin